199 related articles for article (PubMed ID: 30336197)
1. Major vault protein is a direct target of Notch1 signaling and contributes to chemoresistance in triple-negative breast cancer cells.
Xiao YS; Zeng D; Liang YK; Wu Y; Li MF; Qi YZ; Wei XL; Huang WH; Chen M; Zhang GJ
Cancer Lett; 2019 Jan; 440-441():156-167. PubMed ID: 30336197
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Notch1 reverses EMT and chemoresistance to cisplatin via direct downregulation of MCAM in triple-negative breast cancer cells.
Zeng D; Liang YK; Xiao YS; Wei XL; Lin HY; Wu Y; Bai JW; Chen M; Zhang GJ
Int J Cancer; 2020 Jul; 147(2):490-504. PubMed ID: 32020593
[TBL] [Abstract][Full Text] [Related]
3. Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity-An Isobolographic Analysis.
Wawruszak A; Luszczki JJ; Kalafut J; Okla K; Halasa M; Rivero-Muller A; Stepulak A
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357442
[TBL] [Abstract][Full Text] [Related]
4. Y-box binding protein 1 (YB-1) promotes gefitinib resistance in lung adenocarcinoma cells by activating AKT signaling and epithelial-mesenchymal transition through targeting major vault protein (MVP).
Lou L; Wang J; Lv F; Wang G; Li Y; Xing L; Shen H; Zhang X
Cell Oncol (Dordr); 2021 Feb; 44(1):109-133. PubMed ID: 32894437
[TBL] [Abstract][Full Text] [Related]
5. NUMB negatively regulates the epithelial-mesenchymal transition of triple-negative breast cancer by antagonizing Notch signaling.
Zhang J; Shao X; Sun H; Liu K; Ding Z; Chen J; Fang L; Su W; Hong Y; Li H; Li H
Oncotarget; 2016 Sep; 7(38):61036-61053. PubMed ID: 27506933
[TBL] [Abstract][Full Text] [Related]
6. Notch1 signaling regulates the epithelial-mesenchymal transition and invasion of breast cancer in a Slug-dependent manner.
Shao S; Zhao X; Zhang X; Luo M; Zuo X; Huang S; Wang Y; Gu S; Zhao X
Mol Cancer; 2015 Feb; 14(1):28. PubMed ID: 25645291
[TBL] [Abstract][Full Text] [Related]
7. c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun.
Xie X; Kaoud TS; Edupuganti R; Zhang T; Kogawa T; Zhao Y; Chauhan GB; Giannoukos DN; Qi Y; Tripathy D; Wang J; Gray NS; Dalby KN; Bartholomeusz C; Ueno NT
Oncogene; 2017 May; 36(18):2599-2608. PubMed ID: 27941886
[TBL] [Abstract][Full Text] [Related]
8. NOTCH1 activation compensates BRCA1 deficiency and promotes triple-negative breast cancer formation.
Miao K; Lei JH; Valecha MV; Zhang A; Xu J; Wang L; Lyu X; Chen S; Miao Z; Zhang X; Su SM; Shao F; Rajendran BK; Bao J; Zeng J; Sun H; Chen P; Tan K; Chen Q; Wong KH; Xu X; Deng CX
Nat Commun; 2020 Jun; 11(1):3256. PubMed ID: 32591500
[TBL] [Abstract][Full Text] [Related]
9. The putative endogenous AHR ligand ITE reduces JAG1 and associated NOTCH1 signaling in triple negative breast cancer cells.
Piwarski SA; Thompson C; Chaudhry AR; Denvir J; Primerano DA; Fan J; Salisbury TB
Biochem Pharmacol; 2020 Apr; 174():113845. PubMed ID: 32032581
[TBL] [Abstract][Full Text] [Related]
10. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
11. Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and β-catenin genes.
Alkaraki A; Alshaer W; Wehaibi S; Gharaibeh L; Abuarqoub D; Alqudah DA; Al-Azzawi H; Zureigat H; Souleiman M; Awidi A
Breast Cancer; 2020 Sep; 27(5):989-998. PubMed ID: 32328816
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
Gohr K; Hamacher A; Engelke LH; Kassack MU
BMC Cancer; 2017 Nov; 17(1):711. PubMed ID: 29100507
[TBL] [Abstract][Full Text] [Related]
13. Adipocytes promote breast cancer resistance to chemotherapy, a process amplified by obesity: role of the major vault protein (MVP).
Lehuédé C; Li X; Dauvillier S; Vaysse C; Franchet C; Clement E; Esteve D; Longué M; Chaltiel L; Le Gonidec S; Lazar I; Geneste A; Dumontet C; Valet P; Nieto L; Fallone F; Muller C
Breast Cancer Res; 2019 Jan; 21(1):7. PubMed ID: 30654824
[TBL] [Abstract][Full Text] [Related]
14. Transcriptome Profiling of Cisplatin Resistance in Triple-negative Breast Cancer: New Insight into the Role of PI3k/Akt Pathway.
Memar M; Farazmandfar T; Sabaghian A; Shahbazi M; Golalipour M
Curr Mol Med; 2023; 23(6):559-568. PubMed ID: 35585821
[TBL] [Abstract][Full Text] [Related]
15. USP22 Contributes to Chemoresistance, Stemness, and EMT Phenotype of Triple-Negative Breast Cancer Cells by egulating the Warburg Effect via c-Myc Deubiquitination.
Li J; Gao R; Zhang J
Clin Breast Cancer; 2023 Feb; 23(2):162-175. PubMed ID: 36528490
[TBL] [Abstract][Full Text] [Related]
16. Concomitant activation of GLI1 and Notch1 contributes to racial disparity of human triple negative breast cancer progression.
Siddharth S; Parida S; Muniraj N; Hercules S; Lim D; Nagalingam A; Wang C; Gyorffy B; Daniel JM; Sharma D
Elife; 2021 Dec; 10():. PubMed ID: 34889737
[TBL] [Abstract][Full Text] [Related]
17. Triptonide effectively inhibits triple-negative breast cancer metastasis through concurrent degradation of Twist1 and Notch1 oncoproteins.
Zhang M; Meng M; Liu Y; Qi J; Zhao Z; Qiao Y; Hu Y; Lu W; Zhou Z; Xu P; Zhou Q
Breast Cancer Res; 2021 Dec; 23(1):116. PubMed ID: 34922602
[TBL] [Abstract][Full Text] [Related]
18. CLDN6 enhances chemoresistance to ADM via AF-6/ERKs pathway in TNBC cell line MDAMB231.
Yang M; Li Y; Ruan Y; Lu Y; Lin D; Xie Y; Dong B; Dang Q; Quan C
Mol Cell Biochem; 2018 Jun; 443(1-2):169-180. PubMed ID: 29159771
[TBL] [Abstract][Full Text] [Related]
19. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNA TUG1 sponges miR-197 to enhance cisplatin sensitivity in triple negative breast cancer.
Tang T; Cheng Y; She Q; Jiang Y; Chen Y; Yang W; Li Y
Biomed Pharmacother; 2018 Nov; 107():338-346. PubMed ID: 30098551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]